Novavax (Germany) Top Insiders

Novavax Management Team Effectiveness

The company has return on total asset (ROA) of 0.1801 % which means that it generated a profit of $0.1801 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. The Novavax's current Return On Tangible Assets is estimated to increase to -0.12. The current Return On Capital Employed is estimated to decrease to -0.74. At this time, Novavax's Fixed Asset Turnover is most likely to increase slightly in the upcoming years. The Novavax's current Asset Turnover is estimated to increase to 0.41, while Net Tangible Assets are forecasted to increase to (650.1 M). The Novavax's current Common Stock Shares Outstanding is estimated to increase to about 193.7 M, while Net Loss is projected to decrease to (621.8 M). Novavax maintains a total of 162.5 Million outstanding shares. Over half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Novavax in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Novavax, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Novavax Workforce Comparison

The company has Profit Margin (PM) of 0.32 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13.

Novavax Benchmark Summation

Novavax Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Novavax often depends on how effective the management is. Novavax management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novavax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novavax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.